Piramal Pharma Solutions Hits 1,500 ADC Batches at Grangemouth Facility
Event summary
- Piramal Pharma Solutions' Grangemouth facility completed its 1,500th antibody-drug conjugate (ADC) batch on March 16, 2026.
- The milestone batch was a commercial oncology ADC, underscoring the facility's role in critical bioconjugate therapies.
- Grangemouth has developed hundreds of unique bioconjugates and maintains accreditations from the US FDA and MHRA.
- The facility is integral to Piramal's ADCelerate™ program, which streamlines R&D to GMP production.
The big picture
Piramal Pharma Solutions' achievement highlights its long-standing expertise in ADC development and manufacturing, reinforcing its leadership in the bioconjugate space. The milestone comes as the demand for targeted oncology therapies continues to grow, positioning Piramal as a key player in the evolving biopharmaceutical landscape. The integration of the Grangemouth facility's capabilities with Piramal's global network underscores the company's strategic focus on end-to-end solutions for complex biotherapeutics.
What we're watching
- Capacity Expansion
- Whether Piramal can sustain this production pace while expanding its ADC capabilities globally.
- Regulatory Leadership
- How the facility's FDA and MHRA accreditations will influence future regulatory strategies.
- Market Positioning
- The pace at which Piramal can leverage this milestone to strengthen its position in the ADC market.
Related topics